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decision supports are an on-going feature of CPOE.
Another innovation is the linkage of drug allergies

E-call Logging System at DPIC:
The Drug and Poison Information Centre (DPIC) at
the Aga Khan University Hospital (AKUH) operates
round the clock and provides up-to-date, unbiased,
evidence-based information in a timely manner.
The Centre entertains 2300 – 2500 drug and poison

Allergies Information Updated in CPOE

related queries per month from health care professionals and the general public. The manual process
of documentation at DPIC has been computerized
following the in-house development of e-call logging software by our IT team. To our knowledge,
this innovation is one of its kind in this region. The
aim is to have a database of routine medication related information and toxicology management related queries all at one place. Other benefits of the
new software include standardization of the process, quick retrieval of the documented information, a tool for training and development and research; last but not the least, it will also minimise
the cost of paper, a small step towards a paperless
environment.

CPOE Featured with more Robust Allergies
Information:
Drug allergies are common in clinical practice;
cross allergy is
the
presence
of allergy to a
drug and other
relevant similar
drugs. The implementation of the
C o m p u t e r i ze d
Physician Order Entry (CPOE) System at AKUH has
resulted in curtailing many types of medication errors. System modifications to add on to the clinical

with the possible cross allergenic drugs of the same
or related drug class. The system will identify if a
cross allergy is possible with a drug when data on
an allergy is updated in the CPOE system. This will
reduce the chances of accidentally prescribing a
cross-allergy drug to an allergic patient.

Initiation of Point of Care Clinical Pharmacy
Services in Paeds Oncology:
Inception of Point Care Pharmacy (PCP) services is
already contributing to the optimal medication usage and fostering the patient safety in various critical care and selected high risk wards of the hospital. The recent addition to the PCP services is Paeds
Oncology unit. The newly designated pharmacist in
Paeds Oncology is engaged in reviewing the chemotherapy protocols, standardising the IV infusions,
hepatic and renal dose adjustments, cost curtailment, rational use of antibiotics and resolving other
drug related problems.
The physician-pharmacist, nurse-pharmacist and
patient-pharmacist interaction has also increased
to facilitate proper patient care.
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Sulfa Allergy: Myths and Realities
How will you respond to your patient if he/she asks?
I have a sulfa allergy. How would I know if a medicine contains sulfa? Should I simply avoid those drugs that
have the prefix ‘sul’ or ‘sulfa’?”
Answering such queries is never an easy task for health care providers such as doctors, nurses or pharmacists. There is a need of in-depth knowledge of the chemical groups, their interrelation and patient dynamics.
Avoiding only medications with the prefix ‘sul’ or even ‘sulfa’ is not a good rule of thumb if one has a documented sulf allergy.
A typical worry is that a person who is allergic to sulfa drugs may have problems with substances that contain
sulfur. No one is allergic to sulfur itself and sulfur is not present as an isolated element in the body, but in
combination with other elements and, most often, in complex molecules. The primary placement of sulfur
in the human body is in the sulfur containing amino acids: methionine, cysteine, homocysteine and taurine.
Sulfa drugs are more appropriately labelled sulfonamides and are derivatives of para-amino benzoic acid. The
table below lists common medications that contain a sulfonamide component.

Sulfonamide drug classes/individual drugs that may cause allergic reactions
Sulfonamide
Antibiotics
Sulfabenzamide
Sulfacetamide
Sulfadiazine
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulfathiazole
Sulfisoxazole

Thiazide Diuretics
Chlorothiazide
Chlorthalidone
Hydrochlorothiazide
Indapamide
Methyclothiazide
Metolazone

Loop
Diuretics
Furosemide

Sulfonylureas
Chlorpropamide
Tolbutamide
Tolazamide
Glipizide
Glibenclamide
Glimepiride

Carbonic Anhydrase Inhibitors
Acetazolamide

Mechanism of Allergic Reaction:
Sulfa drugs are usually not allergenic by themselves, but when a sulfonamide molecule is metabolised in the
body it is capable of attaching to proteins, thus forming a larger molecule that could serve as an allergen.
Thus, the allergy is not due to the original drug, but the drug-protein
complex. It is estimated that a skin rash occurs in about 3.5 percent
of hospitalised patients receiving sulfonamides, but people with HIV
infection seem to have a considerably higher sensitivity to them.
There are also a number of other medications related to sulfonaSulfa Drugs Allergy
mides. Although the medications noted below are probably safe to be taken if there is a
known sulfa allergy, but one should carefully review the severity of allergy and the risk versus benefit ratio of
using these drugs in such patients. Examples include, but are not limited to:
•
•

Some nonsteroidal anti-inflammatory drugs, such as Celecoxib
Anti Migraine medication, Sumatriptan
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Allergy to Sulfites:
What are sulfites? Sulfites (or sulfiting agents) refer to a group of simple chemicals that include sulphur dioxide and sulfite salts. They are produced naturally in some foods, mainly those undergoing fermentation.
Sulfites are metabolised to sulphur dioxide under certain conditions that depend on concentration, heat,
and pH.
Sulfite Vs Sulfa Drug Allergy: A sulfite reaction is different from a sulfa drug allergy because sulfites and sulfonamides are entirely different chemicals and have unrelated mechanisms of reaction. A person sensitive to
sulfites is no more likely to be allergic to sulfonamides than any other individual and vice versa.
Sulfites in Food Products: Some sulfiting agents are FDA approved preservatives that are added to food and
pharmaceuticals. The more common sulfiting agents are sodium sulfite (Na2SO3), sodium bisulfite (NaHSO3),
and sodium metabisulfite (Na2S2O3).
Because of concerns about sulfite sensitivity, there is a requirement imposed by the FDA to label packaged
foods as having sulfites if they contain as little as 10 parts per million (ppm). Generally, foods with less than
100 ppm of sulfites will not affect sensitive asthmatics, so there is a tenfold safety margin.
However, the FDA has banned adding sulfites to fresh fruits and vegetables offered in restaurants and other
public venues due to concerns that were raised. Juices squeezed from lemons and limes will not have sulfites,
but bottled or dehydrated juice may contain sulfites.
Foods that may contain sulfites
Dried soup mixes
Vegetable juices
Baked goods
Canned or dried fish
Dried fruit
Relishes
Maraschino cherries

Dehydrated vegetables
Shredded coconut
Sauerkraut
Dried noodle meals
Olives
Pickles
Shrimp, lobster, scallops

Lemon and lime juice
Jams and jellies
Grape juice
Wine
Molasses
Gravies
Potatoes

Drug Safety Updates (2010 - 2011)
Serious heart problems in infants and death of the mother may occur in
Terbutaline
pregnancy. Also, oral terbutaline has not been shown to be effective to
prevent or treat preterm labour.
It may increase the risk of a heart attack
Rosiglitazone
Topiramate
Risk for development of cleft lip and/or cleft palate in newborns
Proton Pump Inhibitor (PPIs) Low magnesium levels can be associated with long-term use
There is a potential risk of abnormal muscle movements (extrapyramidal
signs or EPS) and withdrawal symptoms in newborns whose mothers were
Antipsychotic drugs
treated with these drugs during the third trimester of pregnancy.
A recently published meta-analysis suggested that the use of ARBs may
be associated with a small increased risk of cancer. However, FDA has not
concluded that ARBs increase the risk of cancer. The Agency is reviewing
Angiotension Receptor
Blockers (ARBs)
information related to this safety concern and will update when additional
information is available. FDA believes the benefits of ARBs continue to outweigh their potential risks.
FDA informs health care professionals and patients that they should be
aware of the possible increased risk of fractures of the hip, wrist, and
Proton Pump Inhibitor (PPIs)
spine with the use of proton pump inhibitors. Prescribers should weigh the
known benefits against the potential risks when prescribing these drugs.
Source: www.fda.gov

